세계의 니코틴 경구 용해성 박막 시장 예측(-2030년) : 유형, 투여 강도, 유통 채널, 용도, 최종 사용자, 지역별 분석

According to Stratistics MRC, the Global Nicotine Oral Dissolvable Thin Films Market is accounted for $0.11 billion in 2024 and is expected to reach $0.15 billion by 2030 growing at a CAGR of 5.86% during the forecast period. Nicotine oral dissolvable thin films are innovative smoking cessation products designed to deliver nicotine effectively while allowing for rapid absorption through the mucous membranes in the mouth. These thin, flexible films dissolve quickly, providing a discreet and convenient option for users seeking to manage cravings and reduce tobacco dependence. They are typically sugar-free and flavored, appealing to consumers who prefer an alternative to traditional nicotine replacement therapies like gums and patches. As a modern approach to smoking cessation, these films aim to support individuals in their journey to quit smoking.

Market Dynamics:

Driver:

Growing Smoking Cessation Awareness

Growing smoking cessation awareness significantly impacts the market by driving consumer demand for effective quitting aids. As public health campaigns and educational initiatives highlight the risks of smoking, more individuals are seeking alternatives to traditional tobacco products. This increased awareness promotes the adoption of innovative solutions like dissolvable films, which offer a discreet and convenient way to manage cravings. Consequently, manufacturers are encouraged to expand product offerings and marketing efforts, thus it boosts the growth of the market.

Restraint:

Limited Awareness

Limited awareness of nicotine oral dissolvable thin films hinders market growth, as potential users may not know about this effective smoking cessation alternative. This lack of familiarity can result in lower adoption rates, with consumers opting for more traditional nicotine products instead. Consequently, manufacturers face challenges in expanding their market presence and promoting the benefits of these innovative products. Thus, it hampers the growth of the market.

Opportunity:

Convenience and Discretion

Convenience and discretion are key factors influencing the market, as these products offer a portable and easy-to-use alternative for nicotine delivery. Their small size allows users to take them anywhere without drawing attention, appealing to those who seek a more private way to manage cravings. This convenience enhances user experience and encourages adoption, driving demand for these products. As consumers prioritize discreet options for quitting smoking, manufacturers are motivated to innovate and expand their offerings, further boosting market growth. Thus, it drives the growth of the market.

Threat:

Consumer Preferences

Consumer preferences can negatively impact the market if users favor other nicotine replacement products, such as gums, patches, or e-cigarettes. If consumers perceive these alternatives as more effective or easier to use, demand for thin films may decline. Additionally, skepticism about the efficacy or safety of dissolvable films can deter potential users. As preferences shift towards well-established products, manufacturers may face challenges in capturing market share, thus it hinders the growth of the market.

Covid-19 Impact:

The COVID-19 pandemic impacted the nicotine oral dissolvable thin films market by disrupting supply chains and limiting in-person sales due to lockdown measures. However, stress and smoking cessation efforts during the pandemic spurred demand for convenient nicotine delivery methods. As consumers sought alternatives to traditional smoking, awareness and adoption of these films grew, prompting manufacturers to enhance online sales and distribution strategies.

The nicotine gums segment is expected to be the largest during the forecast period

The nicotine gums segment is expected to be the largest during the forecast period because both products aim to deliver nicotine effectively and help manage cravings, which fosters competition within the market. As users compare the convenience and absorption rates of thin films against gums, manufacturers may innovate to enhance their offerings. Additionally, the popularity of nicotine gums can lead to greater awareness of oral dissolvable products, driving demand and encouraging consumers to explore various cessation methods.

The pharmacies segment is expected to have the highest CAGR during the forecast period

The pharmacies segment is expected to have the highest CAGR during the forecast period as they provide consumers with easy access to smoking cessation aids and expert advice on their use. Pharmacies often promote these films as effective alternatives to traditional nicotine delivery methods, enhancing awareness and adoption. Additionally, pharmacists can assist in tailoring cessation strategies for individuals, fostering a supportive environment for quitting smoking. As a result, the presence of pharmacies positively influences market growth and consumer engagement.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to increasing awareness of smoking cessation products and the demand for convenient alternatives to traditional tobacco. These films offer rapid nicotine absorption and discreet use, appealing to consumers seeking effective ways to quit smoking. Additionally, regulatory support and innovations in product formulations are driving market expansion.

Region with highest CAGR:

Asia Pacific is projected to witness the highest CAGR over the forecast period as these films offer discreet and effective nicotine delivery, appealing particularly to younger consumers seeking alternatives to traditional smoking methods. Increased awareness of health risks associated with tobacco use and supportive regulations are further propelling market growth. However, challenges such as regulatory hurdles and competition from alternative nicotine delivery systems may impact market dynamics.

Key players in the market

Some of the key players in Nicotine Oral Dissolvable Thin Films Market include 3M Drug Delivery Systems, Aavishkar Oral Films, Bespak Europe Ltd., Cure Pharmaceutical, GlaxoSmithKline plc, InnovaDerma, IntelGenx Corp., Johnson & Johnson Services, Inc., MonoSol Rx, Nicotine Polacrilex Films LLC, Novartis AG, Ocular Therapeutix, Inc., Oramed Pharmaceuticals Inc., OroVape, Pfizer Inc., PharmaFilm, Revolymer plc, Striptek, Inc., Tesa Labtec GmbH and Vivera Pharmaceuticals, Inc.

Key Developments:

In October 2024, Johnson & Johnson MedTech, announced the first phase of the VOLT Variable Angle Optimized Locking Technology Plating System launch. The innovative system represents an evolution in our fracture management solutions designed to improve stability, enhance performance and increase efficiency.

In October 2024, Johnson & Johnson announced a collaborative effort with the U.S. Agency for International Development (USAID) and the Johnson & Johnson (J&J) Foundation to expand support for health workers across Latin America and the Caribbean.

In August 2024, Pfizer Launched PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the U.S.

Types Covered:

• Nicotine Dissolvable Films
• Nicotine Gums
• Nicotine Lozenges
• Other Types

Dosage Strengths Covered:

• Low Dose (1-2 mg)
• High Dose (4-6 mg)

Distribution Channels Covered:

• Pharmacies
• Online Retailers
• Convenience Stores
• Supermarkets/Hypermarkets

Applications Covered:

• Smoking Cessation
• Nicotine Replacement Therapy (NRT)
• Recreational Use
• Other Applications

End Users Covered:

• Adults
• Teenagers

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Nicotine Oral Dissolvable Thin Films Market, By Type

• 5.1 Introduction
• 5.2 Nicotine Dissolvable Films
• 5.3 Nicotine Gums
• 5.4 Nicotine Lozenges
• 5.5 Other Types

6 Global Nicotine Oral Dissolvable Thin Films Market, By Dosage Strength

• 6.1 Introduction
• 6.2 Low Dose (1-2 mg)
• 6.3 High Dose (4-6 mg)

7 Global Nicotine Oral Dissolvable Thin Films Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Pharmacies
• 7.3 Online Retailers
• 7.4 Convenience Stores
• 7.5 Supermarkets/Hypermarkets

8 Global Nicotine Oral Dissolvable Thin Films Market, By Application

• 8.1 Introduction
• 8.2 Smoking Cessation
• 8.3 Nicotine Replacement Therapy (NRT)
• 8.4 Recreational Use
• 8.5 Other Applications

9 Global Nicotine Oral Dissolvable Thin Films Market, By End User

• 9.1 Introduction
• 9.2 Adults
• 9.3 Teenagers

10 Global Nicotine Oral Dissolvable Thin Films Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 3M Drug Delivery Systems
• 12.2 Aavishkar Oral Films
• 12.3 Bespak Europe Ltd.
• 12.4 Cure Pharmaceutical
• 12.5 GlaxoSmithKline plc
• 12.6 InnovaDerma
• 12.7 IntelGenx Corp.
• 12.8 Johnson & Johnson Services, Inc.
• 12.9 MonoSol Rx
• 12.10 Nicotine Polacrilex Films LLC
• 12.11 Novartis AG
• 12.12 Ocular Therapeutix, Inc.
• 12.13 Oramed Pharmaceuticals Inc.
• 12.14 OroVape
• 12.15 Pfizer Inc.
• 12.16 PharmaFilm
• 12.17 Revolymer plc
• 12.18 Striptek, Inc.
• 12.19 Tesa Labtec GmbH
• 12.20 Vivera Pharmaceuticals, Inc.